Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Immunovia AB ( (SE:IMMNOV) ) just unveiled an update.
Immunovia announced that the Centers for Medicare & Medicaid Services (CMS) has issued a preliminary payment determination for its PancreaSure test, setting a price of $897. This decision marks a crucial step in the process of securing Medicare reimbursement, following the acquisition of a Current Procedural Terminology (CPT) code. The final payment decision will be made in November, with the rate effective from January 2026, potentially impacting the company’s market positioning and stakeholder interests.
More about Immunovia AB
Immunovia AB is a diagnostic company focused on increasing survival rates for pancreatic cancer patients through early detection. The company specializes in developing and commercializing tests that detect proteins and antibodies indicating pancreatic cancer, collaborating with healthcare providers, experts, and advocacy groups to serve high-risk individuals. The USA is a significant market for their services, with an estimated 1.8 million high-risk individuals potentially benefiting from annual surveillance testing.
Average Trading Volume: 10,144,419
Technical Sentiment Signal: Hold
Current Market Cap: SEK204.2M
For detailed information about IMMNOV stock, go to TipRanks’ Stock Analysis page.